Delcath Jumps 28% to 52-Week High as Q3 Crushes Estimates, Guidance Raised
DCTH has more than doubled off its 52-week low of $8.12 on elevated volume (2.8× avg).
Summary
Delcath posted Q3 EPS of 17 cents on sales of $35.1 million, versus consensus for a 9-cent loss on $26 million — a wide beat on both lines. The company raised full-year revenue guidance to $115 million-$117 million from $104 million-$108 million, also above the $106.4 million analysts expected. Shares gained 28% to $19.12 late Monday morning after touching a 52-week high of $19.35. The move extends this morning's earnings headline into a new session with a materially larger price reaction, and the 10-Q backs it up with an 89% gross margin, $7.1 million of operating income and $104.3 million in cash and investments.
At the time of this announcement, DCTH was trading at $18.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $651.3M. The 52-week trading range was $8.12 to $19.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.